Vitamine K : interactions médicamenteuses

Patients with a hemorrhagic diathesis (e.g., hemophilia, hypoprothrombinemia, von Willebrand's disease, the thrombocytopenias, thrombasthenia and other ill-defined hereditary platelet dysfunctions, severe vitamin K deficiency and severe liver damage). (notice Butalbital, aspirine et caféine, Contre-indications)

WARNING: SERIOUS ADVERSE REACTIONS OR DEATH IN PATIENTS WITH COMPLETE DPD DEFICIENCY and INCREASED RISK OF BLEEDING WITH CONCOMITANT USE OF VITAMIN K ANTAGONISTS Increased risk of serious adverse reactions or death in patients with complete DPD deficiency • Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary. (notice Capécitabine, Mise en garde encadrée)

Do not administer agents that enhance the risk of hemorrhage with fondaparinux sodium unless essential for the management of the underlying condition, such as vitamin K antagonists for the treatment of VTE. (notice Fondaparinux, Mises en garde et précautions)

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (notice Fosphénytoïne, Mises en garde et précautions)

A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. (notice Phénytoïne, Mises en garde et précautions)

Postmarketing reports suggest that concomitant administration of high doses of cefazolin and rifampin may prolong the prothrombin time, leading to severe vitamin K–dependent coagulation disorders that may be life-threatening or fatal. (notice Rifampicine, Mises en garde)

La vitamine K réduit l'effet anticoagulant de la warfarine ; des changements soudains de l'apport, par les compléments alimentaires ou l'alimentation, peuvent dérégler l'INR. (NIH Office of Dietary Supplements, Vitamin K)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (notice Apixaban, Mises en garde et précautions)

Some patients had serious bleeding including intracranial, retroperitoneal, and gastrointestinal requiring blood transfusion and/or administration of vitamin K. (notice Bicalutamide, Mises en garde et précautions)

This can adversely affect patients with inherited (i.e. hemophilia) or acquired (i.e. liver disease or vitamin K deficiency) bleeding disorders. (notice Butalbital, aspirine, caféine et codéine, Mises en garde et précautions)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated (5.5) (notice Céfazoline, Mises en garde et précautions)

Prothrombin time should be monitored in patients at risk, and exogenous vitamin K administered as indicated. (notice Céfépime, Mises en garde et précautions)

Prothrombin time should be monitored in patients at risk and exogenous vitamin K administered as indicated. (notice Céfixime, Mises en garde et précautions)

Prothrombin time should be monitored and exogenous vitamin K administered as indicated. (notice Céfotétan, Mises en garde)

Patients with impaired vitamin K synthesis or low vitamin K stores (e.g., chronic hepatic disease and malnutrition) may require monitoring of prothrombin time during Ceftriaxone for Injection and Dextrose Injection treatment. (notice Ceftriaxone, Mises en garde et précautions)

Vitamin K or Fat-Soluble Vitamin Deficiencies: Colesevelam hydrochloride may decrease absorption of fat-soluble vitamins. (notice Colésévélam, Mises en garde et précautions)

For patients with APS (especially those who are triple-positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (notice Dabigatran, Mises en garde et précautions)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (notice Édoxaban, Mises en garde et précautions)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (notice Lévothyroxine et liothyronine, Interactions médicamenteuses)

Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability. (notice Néomycine, Interactions médicamenteuses)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (notice Orlistat, Interactions médicamenteuses)

Increased prothrombin time has been reported in patients concomitantly treated with pentoxifylline and vitamin K antagonists. (notice Pentoxifylline, Interactions médicamenteuses)

Drug Interactions Anticoagulants (oral) : Due to the potential inhibition of vitamin K activity by propylthiouracil, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. (notice Propylthiouracile, Interactions médicamenteuses)

Warfarin and oral anticoagulants Cinchona alkaloids, including quinine, may have the potential to depress hepatic enzyme synthesis of vitamin K-dependent coagulation pathway proteins and may enhance the action of warfarin and other oral anticoagulants. (notice Quinine, Interactions médicamenteuses)

For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy. (notice Rivaroxaban, Mises en garde et précautions)

In vitro experiments demonstrated additional aPTT and PT(INR) prolongations for sugammadex in combination with vitamin K antagonists, unfractionated heparin, low molecular weight heparinoids, rivaroxaban, and dabigatran up to ~25% and ~50% at C max levels of sugammadex corresponding to 4 mg/kg and 16 mg/kg doses, respectively. (notice Sugammadex, Mises en garde et précautions)

Drug Interactions Anticoagulants (oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers… (notice Thiamazole, Interactions médicamenteuses)

Methylergonovine maleate has been administered instead of vitamin K and Hepatitis B vaccine, medications which are routinely administered to the newborn. (notice Méthylergométrine, Mises en garde)

Cutaneous Reactions Parenteral administration of vitamin K replacements (including phytonadione injectable emulsion) may cause cutaneous reactions. (notice Phytoménadione (vitamine K1), Mises en garde et précautions)

Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. (notice Primidone, Mises en garde)